Related Experiment Videos
[Laboratory and clinical studies on levofloxacin]
K Tanaka1, M Iwamoto, S Maesaki
1Second Department of Internal Medicine, School of Medicine, Nagasaki University.
The Japanese Journal of Antibiotics
|May 1, 1992
Summary
Levofloxacin (LVFX) demonstrates potent broad-spectrum antimicrobial activity, outperforming other fluoroquinolones against Gram-positive bacteria and showing comparable efficacy against Gram-negative strains. This new antibiotic effectively penetrates lung tissue and shows promising clinical efficacy for respiratory tract infections with a favorable safety profile.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Context:
- Levofloxacin (LVFX) is a novel broad-spectrum fluoroquinolone antibiotic.
- Comparative evaluations are crucial for understanding the therapeutic potential of new antimicrobial agents.
Purpose:
- To evaluate the in vitro and in vivo efficacy and safety of levofloxacin (LVFX) compared to ciprofloxacin (CPFX), ofloxacin (OFLX), and norfloxacin (NFLX).
Summary:
- Levofloxacin exhibited superior in vitro activity against Gram-positive bacteria and comparable or superior activity against Gram-negative bacteria compared to other tested fluoroquinolones.
- Pharmacokinetic studies showed good penetration of LVFX into sputum, indicating effective lung tissue distribution after oral administration.
- Clinical trials demonstrated a high efficacy rate of 78.6% for respiratory tract infections with generally mild and transient adverse reactions.
Impact:
- Levofloxacin presents a promising therapeutic option for respiratory tract infections due to its broad-spectrum activity, favorable pharmacokinetic profile, and good safety.
- The findings support the clinical utility of levofloxacin as an effective treatment for bacterial respiratory infections.